Credit: Thinkstock. KPI-012 is a topically dosed ophthalmic therapy designed using the Company's human mesenchymal stem cell secretome platform. The Food and Drug Administration (FDA) has granted Fast ...

-- Study did not meet primary endpoint of complete healing of PCED at Week 8; secondary endpoints also did not achieve statistical significance -- -- KPI-012 was well-tolerated with no ...

Eric Donnenfeld’s corneal health case presentations and panel discussion at OSN New York are always popular with meeting ...

-- On-track to initiate Phase 2b trial in 4Q 2022, with topline data expected in 1Q 2024 -- -- Cash runway extended into 1Q 2025, pending receipt of second tranche from previously announced financing, ...

Please provide your email address to receive an email when new articles are posted on . A 67-year-old man was referred to the cornea clinic with complaints of progressive vision decline, mild pain and ...

ARLINGTON, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization ...

There were 35 eyes of 33 patients, with a mean age of 68.2±19.5 years (range: 17–99 years). There were 25 men and 8 women. Median follow-up was 110 days (mean: 164.6 days; range: 30–960 days). The ...

A 68-year-old insulin-dependent diabetic male patient presented with progressive pain, redness, photophobia, tearing, and decreased vision of 1-month duration in his left eye. He had history of ...